SE539450C2 - Imatinib for use in the treatment of stroke - Google Patents
Imatinib for use in the treatment of stroke Download PDFInfo
- Publication number
- SE539450C2 SE539450C2 SE1650260A SE1650260A SE539450C2 SE 539450 C2 SE539450 C2 SE 539450C2 SE 1650260 A SE1650260 A SE 1650260A SE 1650260 A SE1650260 A SE 1650260A SE 539450 C2 SE539450 C2 SE 539450C2
- Authority
- SE
- Sweden
- Prior art keywords
- imatinib
- patient
- stroke
- administered
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (sv) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
| SI201730931T SI3423060T1 (sl) | 2016-02-29 | 2017-02-27 | Imatinib za uporabo pri zdravljenju možganske kapi |
| PT177603990T PT3423060T (pt) | 2016-02-29 | 2017-02-27 | Imatinib para utilização no tratamento de acidente vascular cerebral |
| CN201780013732.6A CN108697711A (zh) | 2016-02-29 | 2017-02-27 | 伊马替尼在治疗中风中的用途 |
| US16/080,529 US10953010B2 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| HUE17760399A HUE056798T2 (hu) | 2016-02-29 | 2017-02-27 | Imatinib stroke kezelésében való alkalmazásra |
| ES17760399T ES2895432T3 (es) | 2016-02-29 | 2017-02-27 | Imatinib para uso en el tratamiento de accidente cerebrovascular |
| RS20211286A RS62465B1 (sr) | 2016-02-29 | 2017-02-27 | Imatinib za upotrebu u lečenju moždanog udara |
| RU2019122730A RU2739382C1 (ru) | 2016-02-29 | 2017-02-27 | Иматиниб для применения для лечения инсульта |
| JP2018545843A JP6914957B2 (ja) | 2016-02-29 | 2017-02-27 | 脳卒中の処置における使用のためのイマチニブ |
| EP17760399.0A EP3423060B1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| HRP20211621TT HRP20211621T1 (hr) | 2016-02-29 | 2017-02-27 | Imatinib za uporabu u liječenju moždanog udara |
| PL17760399T PL3423060T3 (pl) | 2016-02-29 | 2017-02-27 | Imatynib do stosowania w leczeniu udaru mózgu |
| PCT/SE2017/050183 WO2017151043A1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| AU2017227515A AU2017227515B2 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| LTEPPCT/SE2017/050183T LT3423060T (lt) | 2016-02-29 | 2017-02-27 | Imatinibas, skirtas naudoti insulto gydymui |
| CN202411509669.3A CN119523986A (zh) | 2016-02-29 | 2017-02-27 | 伊马替尼在治疗中风中的用途 |
| DK17760399.0T DK3423060T3 (da) | 2016-02-29 | 2017-02-27 | Imatinib til anvendelse til behandling af slagtilfælde |
| US17/186,303 US20210236488A1 (en) | 2016-02-29 | 2021-02-26 | Imatinib for use in the treatment of stroke |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (sv) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE1650260A1 SE1650260A1 (sv) | 2017-08-30 |
| SE539450C2 true SE539450C2 (sv) | 2017-09-26 |
Family
ID=59744327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1650260A SE539450C2 (sv) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953010B2 (sv) |
| EP (1) | EP3423060B1 (sv) |
| JP (1) | JP6914957B2 (sv) |
| CN (2) | CN119523986A (sv) |
| AU (1) | AU2017227515B2 (sv) |
| DK (1) | DK3423060T3 (sv) |
| ES (1) | ES2895432T3 (sv) |
| HR (1) | HRP20211621T1 (sv) |
| HU (1) | HUE056798T2 (sv) |
| LT (1) | LT3423060T (sv) |
| PL (1) | PL3423060T3 (sv) |
| PT (1) | PT3423060T (sv) |
| RS (1) | RS62465B1 (sv) |
| RU (1) | RU2739382C1 (sv) |
| SE (1) | SE539450C2 (sv) |
| SI (1) | SI3423060T1 (sv) |
| WO (1) | WO2017151043A1 (sv) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| CN114306342B (zh) * | 2020-09-30 | 2024-06-28 | 江苏先声药业有限公司 | 一种注射用伊马替尼盐的药物组合物及其制备方法 |
| US20230279120A1 (en) * | 2021-11-09 | 2023-09-07 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
| EP4311539A1 (en) | 2022-07-29 | 2024-01-31 | Artorange Ltd. | Imatinib formulation for parenteral administration |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| AU2007240429A1 (en) * | 2006-04-17 | 2007-11-01 | Ludwig Institute For Cancer Research Ltd | Methods and compositions for modulation of blood-neural barrier |
| US7977348B2 (en) * | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
| KR20090061055A (ko) * | 2006-10-26 | 2009-06-15 | 시코르, 인크. | 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법 |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| TR201911199T4 (tr) * | 2009-03-27 | 2019-08-21 | Moleac Pte Ltd | Hücre büyümesini arttırmak için tedavi. |
-
2016
- 2016-02-29 SE SE1650260A patent/SE539450C2/sv not_active IP Right Cessation
-
2017
- 2017-02-27 RS RS20211286A patent/RS62465B1/sr unknown
- 2017-02-27 HR HRP20211621TT patent/HRP20211621T1/hr unknown
- 2017-02-27 EP EP17760399.0A patent/EP3423060B1/en active Active
- 2017-02-27 PT PT177603990T patent/PT3423060T/pt unknown
- 2017-02-27 LT LTEPPCT/SE2017/050183T patent/LT3423060T/lt unknown
- 2017-02-27 RU RU2019122730A patent/RU2739382C1/ru active
- 2017-02-27 SI SI201730931T patent/SI3423060T1/sl unknown
- 2017-02-27 ES ES17760399T patent/ES2895432T3/es active Active
- 2017-02-27 AU AU2017227515A patent/AU2017227515B2/en active Active
- 2017-02-27 HU HUE17760399A patent/HUE056798T2/hu unknown
- 2017-02-27 CN CN202411509669.3A patent/CN119523986A/zh active Pending
- 2017-02-27 US US16/080,529 patent/US10953010B2/en active Active
- 2017-02-27 JP JP2018545843A patent/JP6914957B2/ja active Active
- 2017-02-27 CN CN201780013732.6A patent/CN108697711A/zh active Pending
- 2017-02-27 DK DK17760399.0T patent/DK3423060T3/da active
- 2017-02-27 PL PL17760399T patent/PL3423060T3/pl unknown
- 2017-02-27 WO PCT/SE2017/050183 patent/WO2017151043A1/en not_active Ceased
-
2021
- 2021-02-26 US US17/186,303 patent/US20210236488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUE056798T2 (hu) | 2022-03-28 |
| EP3423060A4 (en) | 2020-01-01 |
| HRP20211621T1 (hr) | 2022-02-04 |
| PL3423060T3 (pl) | 2022-01-10 |
| JP2019507165A (ja) | 2019-03-14 |
| US10953010B2 (en) | 2021-03-23 |
| SE1650260A1 (sv) | 2017-08-30 |
| US20190030030A1 (en) | 2019-01-31 |
| US20210236488A1 (en) | 2021-08-05 |
| AU2017227515B2 (en) | 2022-03-24 |
| PT3423060T (pt) | 2021-10-20 |
| LT3423060T (lt) | 2021-11-10 |
| CN108697711A (zh) | 2018-10-23 |
| SI3423060T1 (sl) | 2021-11-30 |
| JP6914957B2 (ja) | 2021-08-04 |
| CN119523986A (zh) | 2025-02-28 |
| WO2017151043A1 (en) | 2017-09-08 |
| RU2739382C1 (ru) | 2020-12-23 |
| DK3423060T3 (da) | 2021-10-25 |
| ES2895432T3 (es) | 2022-02-21 |
| AU2017227515A1 (en) | 2018-08-30 |
| EP3423060A1 (en) | 2019-01-09 |
| EP3423060B1 (en) | 2021-07-21 |
| RS62465B1 (sr) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210236488A1 (en) | Imatinib for use in the treatment of stroke | |
| Sao et al. | Pain after laparoscopic surgery: Focus on shoulder-tip pain after gynecological laparoscopic surgery | |
| Diringer et al. | Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit | |
| Polifka | Is there an embryopathy associated with first‐trimester exposure to angiotensin‐converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence | |
| Du et al. | Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery | |
| AU2007218709A1 (en) | Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke | |
| Awad et al. | Dabigatran, intracranial hemorrhage, and the neurosurgeon | |
| RU2542455C2 (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| Guo et al. | Clinical efficacy and prognosis of aspirin combined with clopidogrel in patients with cerebral hemorrhage after operation. | |
| RU2845317C1 (ru) | Способ лечения постковидного синдрома | |
| Tempaku | Intracranial hemorrhage during administration of a novel oral anticoagulant | |
| AL SHAMSI et al. | WCN23-0109 MANAGEMENT OF ASYMPTOMATIC ANGIOMYOLIPOMA IN PREGNANCY | |
| Naeem et al. | Posterior Fossa Hemorrhage Following the Use of Low-Molecular-Weight Heparin: Lessons Learned and Recommendations for the Treatment and Prophylaxis of Postoperative Venous Thromboembolism | |
| CN115475165B (zh) | 马来酸茚达特罗在出血性脑损伤相关疾病中的应用 | |
| ALLAM | WCN23-0127 KIDNEY OUT COMES IN SUDANSES CHILDREN WITH LUPUS NEPHRITIES | |
| Wang et al. | Pre-operative Embolization of a Cerebellar Hemangioblastoma Using Polyvinyl Alcohol (PVA) and Target Tetra 360 Detachable Coil | |
| Alkanat et al. | Dermatologic Reactions Following COVID-19 Vaccination: A Case Series. | |
| IVH | Special Disease Management | |
| KR20250114057A (ko) | 맥관 기형용 의약 조성물 및 맥관 기형의 치료 방법 | |
| Katayoun Vahedi | Surgery for acute ischemic stroke | |
| US20180243247A1 (en) | Drug combinations for cerebrovascular disease | |
| Rahman et al. | Effect of Tamsulosin on Treatment of Lower Ureteric Calculi | |
| CN121221781A (zh) | 一种用于预防胆囊结石的药物组合物 | |
| RU2578472C1 (ru) | Способ лечения злокачественной опухоли головного мозга | |
| ARJUNDAS et al. | Management of acute ischaemic stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |